Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Description of key information

The test item MAA was tested in acute studies by oral and dermal application on rats. The acute oral study was performed before implementation of the corresponding OECD- and GLP-guidelines in 1975, however it provides sufficient information to assess it as key study having Klimisch 2. There was an additional acute oral toxicity study published in the JETOC Information sheet No. 43 of April 2000 - Special Issue no. 6. A complete English translation of the report is not available, however the LD50 of this GLP-study was reported to be > 2000 mg/kg.
An additional Klimisch 3, non-guideline conform study with inhalative, intraperitoneal and oral application is available, but was not further assessed due to its poor quality and limited information).

Key value for chemical safety assessment

Acute toxicity: via oral route

Link to relevant study records
Reference
Endpoint:
acute toxicity: oral
Type of information:
experimental study
Adequacy of study:
key study
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
other: see 'Remark'
Remarks:
the study was performed before GLP- and OECD-testing guidelines were available and in force; therefore the study was considered to have Klimisch 2, however itprovides enough information to assess the acute toxicity after to rats after oral application
Qualifier:
equivalent or similar to guideline
Guideline:
OECD Guideline 401 (Acute Oral Toxicity)
Deviations:
no
GLP compliance:
no
Remarks:
GLP-guidelines not yet in force at date of the study
Test type:
standard acute method
Limit test:
no
Species:
rat
Strain:
not specified
Sex:
male/female
Details on test animals or test system and environmental conditions:
Fasted albino rats were used in this study.
Route of administration:
oral: gavage
Vehicle:
unchanged (no vehicle)
Details on oral exposure:
The product under test was placed in a glass syringe and introduced through the esophagus into the stomach with a stainless steel catheter.
Doses:
6 dose groups (males & females) with dosages of:
- 0 mg/kg (control)
- 1000 mg/kg
- 2000 mg/kg
- 2500 mg/kg
- 3200 mg/kg
- 4000 mg/kg
- 8000 mg/kg
No. of animals per sex per dose:
Five animals per sex and dose
Control animals:
yes
Details on study design:
A group of approximately 70 albino male and female rats, fasted for twenty-four hours were employed to establish an LD50 range for each product under test. Young adult rats which had not been used for previous test purposes were assigned to various dose levels at random. Both sexes were equally distributed. Body weight of the rats was 200-300 grams at the beginning of the study. Animals on the same dosage level were then placed in a common cage with free access to food and water. The animals were observed daily for a two week period. No postmortem, or histopathology examinations were performed in this particular study.
Statistics:
no data
Preliminary study:
No preliminary test performed.
Sex:
male
Dose descriptor:
LD50
Effect level:
2 580 mg/kg bw
Based on:
test mat.
95% CL:
2 230 - 2 980
Sex:
female
Dose descriptor:
LD50
Effect level:
3 370 mg/kg bw
Based on:
test mat.
95% CL:
2 920 - 3 900
Mortality:
No mortality was observed at dose concentrations of 1000 and 2000 mg/kg. Animals were found dead at 2500 mg/kg and above in males and at 3200 mg/kg and above in females. Details are given in the table below.
Clinical signs:
other: Males & females dosed at 1.0 g/kg and 2.0 g/kg were sluggish and unkempt following intubation. Normalcy prevailed within 48 hours. Lethargy, nasal hemorrhage and dirty unkempt coats were noted in all animals dosed at levels ranging from 2.5 g/kg. to 4.0 g
Gross pathology:
No postmortem, or histopathology examinations were performed in this particular study.
Other findings:
no data

Mortality:

Dose Level (mg/kg)

No. of deaths (males)

Number of deaths (females)

1000

0

0

2000

0

0

2500

3

0

3200

4

2

4000

5 (4 at day 1 & 1 at day 3)

4

8000

5

5

Interpretation of results:
not classified
Remarks:
Migrated information Criteria used for interpretation of results: EU
Conclusions:
The acute oral toxicity on Albino rats was determined to be 2580 mg/kg for males and 3370 mg/kg for females.
Executive summary:

The study was carried out equivalent or similar to EU Method B.1 and OECD Guideline 401 (Acute Oral Toxicity). 6 groups of 10 rats (5 male, 5 female) were treated by gavage with doses from 1000 up to 8000 mg/kg.Males & females dosed at 1.0 g/kg and 2.0 g/kg were sluggish and unkempt following intubation. Normalcy prevailed within 48 hours. Lethargy, nasal hemorrhage and dirty unkempt coats were noted in all animals dosed at levels ranging from 2.5 g/kg. to 4.0 g/kg. Death animals were observed at dose levels of 2500 mg/kg and above. At 8000 mg/kg, the animals were comatose immediately after forced feeding and succumbed within 15 minutes.The LD50 value obtained for males was 2580 mg/kg bw and for females 3370 mg/kg bw.

Endpoint conclusion
Endpoint conclusion:
no adverse effect observed
Dose descriptor:
LD50
Value:
2 580 mg/kg bw

Acute toxicity: via inhalation route

Endpoint conclusion
Endpoint conclusion:
no study available

Acute toxicity: via dermal route

Link to relevant study records
Reference
Endpoint:
acute toxicity: dermal
Type of information:
experimental study
Adequacy of study:
key study
Study period:
Between 30 January 2012 and 13 February 2012
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
other: study report was conclusive, done to a valid guideline and conducted under GLP conditions.
Qualifier:
according to guideline
Guideline:
OECD Guideline 402 (Acute Dermal Toxicity)
Deviations:
no
Qualifier:
according to guideline
Guideline:
EU Method B.3 (Acute Toxicity (Dermal))
Deviations:
no
GLP compliance:
yes (incl. QA statement)
Test type:
standard acute method
Limit test:
yes
Species:
rat
Strain:
Wistar
Sex:
male/female
Details on test animals or test system and environmental conditions:
Five male and five female Wistar (RccHan:WIST) strain rats were supplied by Harlan Laboratories UK Ltd., Oxon, UK. On receipt the animals were randomly allocated to cages. The females were nulliparous and non pregnant. After an acclimatisation period of at least five days the animals were selected at random and given a number unique within the study by indelible ink-marking on the tail and a number written on a cage card. At the start of the study the animals weighed at least 200g, and were eight to twelve weeks of age. The weight variation did not exceed ±20% of the mean weight for each sex.
The animals were housed in suspended solid floor polypropylene cages furnished with woodflakes. The animals were housed individually during the 24 Hour exposure period and in groups of five, by sex, for the remainder of the study. Free access to mains drinking water and food (2014C Teklad Global Rodent diet supplied by Harlan Laboratories UK Ltd., Oxon, UK) was allowed throughout the study. The diet, drinking water and bedding were routinely analysed and were considered not to contain any contaminants that could reasonably be expected to affect the purpose or integrity of the study.
The temperature and relative humidity were set to achieve limits of 19 to 25°C and 30 to 70% respectively. Any occasional deviations from these targets were considered not to have affected the purpose or integrity of the study. The rate of air exchange was at least fifteen changes per hour and the lighting was controlled by a time switch to give twelve hours continuous light (06:00 to 18:00) and twelve hours darkness.
The animals were provided with environmental enrichment items which were considered not to contain any contaminant of a level that might have affected the purpose or integrity of the study.
Type of coverage:
semiocclusive
Vehicle:
unchanged (no vehicle)
Details on dermal exposure:
The calculated volume of test item, as received, was applied as evenly as possible to an area of shorn skin (approximately 10% of the total body surface area) using a graduated syringe.
Duration of exposure:
24 hours
Doses:
2000 mg /kg body weight
No. of animals per sex per dose:
5 males & 5 females
Control animals:
not required
Details on study design:
On the day before treatment the back and flanks of each animal were clipped free of hair.
Using available information on the toxicity of the test item, a single group of animals was treated as follows:

Dose Level Specific Gravity Dose Volume Number of Rats
(mg/kg) (ml/kg) Male Female
2000 1.077 1.86 5 5


The calculated volume of test item, as received, was applied as evenly as possible to an area of shorn skin (approximately 10% of the total body surface area) using a graduated syringe. A piece of surgical gauze was placed over the treatment area and semi occluded with a piece of self adhesive bandage. The animals were caged individually for the 24 Hour exposure period. Shortly after dosing the dressings were examined to ensure that they were securely in place.
After the 24 Hour contact period the bandage was carefully removed and the treated skin and surrounding hair wiped with cotton wool moistened with distilled water to remove any residual test item. The animals were returned to group housing for the remainder of the study period.
The animals were observed for deaths or overt signs of toxicity ½, 1, 2 and 4 hours after dosing and subsequently once daily for fourteen days.
After removal of the dressings and subsequently once daily for fourteen days, the test sites were examined for evidence of primary irritation and scored according to the following scale from Draize J H (1977) "Dermal and Eye Toxicity Tests" In: Principles and Procedures for Evaluating the Toxicity of Household Substances, National Academy of Sciences, Washington DC p.31:

EVALUATION OF SKIN REACTIONS
Erythema and Eschar Formation Value

No erythema 0
Very slight erythema (barely perceptible) 1
Well-defined erythema 2
Moderate to severe erythema 3
Severe erythema (beef redness) to slight eschar formation (injuries in depth) 4

Oedema Formation

No oedema 0
Very slight oedema (barely perceptible) 1
Slight oedema (edges of area well-defined by definite raising) 2
Moderate oedema (raised approximately 1 millimetre) 3
Severe oedema (raised more than 1 millimetre and extending beyond the area of exposure) 4

Any other skin reactions, if present were also recorded.
Individual bodyweights were recorded prior to application of the test item on Day 0 and on Days 7 and 14.
At the end of the study the animals were killed by cervical dislocation. All animals were subjected to gross necropsy. This consisted of an external examination and opening of the abdominal and thoracic cavities. The appearance of any macroscopic abnormalities was recorded. No tissues were retained.

Statistics:
No statistical analysis was performed.
Preliminary study:
no pretest performed
Sex:
male/female
Dose descriptor:
LD50
Effect level:
> 2 000 mg/kg bw
Based on:
test mat.
Remarks on result:
other: 95% confidence limits not reported.
Mortality:
There were no deaths.
Clinical signs:
other: There were no signs of systemic toxicity.
Gross pathology:
No abnormalities were noted at necropsy.
Other findings:
Dermal Reactions: There were no signs of dermal irritation.

Evaluation of Data:

Data evaluations included the relationship, if any, between the exposure of the animal to the test item and the incidence and severity of all abnormalities including behavioural and clinical observations, gross lesions, bodyweight changes, mortality and any other toxicological effects.

Using the mortality data obtained, an estimate of the acute dermal median lethal dose (LD50) of the test item was made.

The results were also interpreted according to Regulation (EC) No. 1272/2008 for classification and labelling of dangerous substances and the Globally Harmonised System of Classification and Labelling of Chemicals.

Table 1              Individual Clinical Observations and Mortality Data

Dose Level

mg/kg

Animal Number and Sex

Effects Noted After Initiation of Exposure (Hours)

Effects Noted After Initiation of Exposure (Days)

½

1

2

4

1

2

3

4

5

6

7

8

9

10

11

12

13

14

2000

1-0

Male

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

1-1

Male

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

1-2

Male

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

1-3

Male

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

1-4

Male

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

2-0

Female

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

2-1

Female

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

2-2

Female

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

2-3

Female

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

2-4

Female

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0

0


0 = No signs of systemic toxicity

Table 2              Individual Dermal Reactions - Males

Dose Level mg/kg

Animal Number and Sex

Observation

Effects Noted After Initiation of Exposure (Days)

1

2

3

4

5

6

7

8

9

10

11

12

13

14

2000

1-0

Male

Erythema

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Oedema

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Other

0

0

0

0

0

0

0

0

0

0

0

0

0

0

1-1

Male

Erythema

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Oedema

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Other

0

0

0

0

0

0

0

0

0

0

0

0

0

0

1-2

Male

Erythema

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Oedema

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Other

0

0

0

0

0

0

0

0

0

0

0

0

0

0

1-3

Male

Erythema

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Oedema

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Other

0

0

0

0

0

0

0

0

0

0

0

0

0

0

1-4

Male

Erythema

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Oedema

0

0

0

0

0

0

0

0

0

0

0

0

0

0

Other

0

0

0

0

0

0

0

0

0

0

0

0

0

0


0 = No reactions

Table 4              Individual Bodyweights and Weekly Bodyweight Changes

Dose Level mg/kg

Animal Number and Sex

Bodyweight (g) at Day

Bodyweight Change (g) During Week

0

7

14

1

2

2000

1-0 Male

244

275

293

31

18

1-1 Male

234

259

290

25

31

1-2 Male

239

275

298

36

23

1-3 Male

234

254

280

20

26

1-4 Male

226

252

273

26

21

2-0 Female

201

211

222

10

11

2-1 Female

211

233

243

22

10

2-2 Female

205

214

224

9

10

2-3 Female

224

225

236

1

11

2-4 Female

205

212

224

7

12

Table 5              Individual Necropsy Findings

Dose Level

mg/kg

Animal Number
and Sex

Time of Death

Macroscopic Observations

2000

1-0

Male

Killed Day 14

No abnormalities detected

1-1

Male

Killed Day 14

No abnormalities detected

1-2

Male

Killed Day 14

No abnormalities detected

1-3

Male

Killed Day 14

No abnormalities detected

1-4

Male

Killed Day 14

No abnormalities detected

2-0

Female

Killed Day 14

No abnormalities detected

2-1

Female

Killed Day 14

No abnormalities detected

2-2

Female

Killed Day 14

No abnormalities detected

2-3

Female

Killed Day 14

No abnormalities detected

2-4

Female

Killed Day 14

No abnormalities detected

Interpretation of results:
not classified
Remarks:
Migrated information Criteria used for interpretation of results: EU
Conclusions:
The acute dermal median lethal dose (LD50) of the test item in the Wistar strain rat was found to be greater than 2000 mg/kg bodyweight.
Executive summary:

The study was performed according to OECD Guidelines No. 402 and EU-Method B3. A group of ten animals (five males and five females) was given a single, 24 hour, semi‑occluded dermal application of the undiluted test item to intact skin at a dose level of 2000 mg/kg bodyweight. There were no deaths and no signs of systemic toxicity. All animals showed expected gains in bodyweight over the study period. No abnormalities were noted at necropsy. The acute dermal median lethal dose (LD50) of the test item in the Wistar strain rat was found to be greater than 2000 mg/kg body weight.

Endpoint conclusion
Endpoint conclusion:
no adverse effect observed
Dose descriptor:
LD50
Value:
2 000 mg/kg bw

Additional information

Key study: Acute toxicity – oral

A study was carried out equivalent or similar to EU Method B.1 and OECD Guideline 401 (Acute Oral Toxicity). 6 groups of 10 rats (5 male, 5 female) were treated by gavage with doses from 1000 up to 8000 mg/kg. Males & females dosed at 1.0 g/kg and 2.0 g/kg were sluggish and unkempt following intubation. Normalcy prevailed within 48 hours. Lethargy, nasal hemorrhage and dirty unkempt coats were noted in all animals dosed at levels ranging from 2.5 g/kg. to 4.0 g/kg. Death animals were observed at dose levels of 2500 mg/kg and above. At 8000 mg/kg, the animals were comatose immediately after forced feeding and succumbed within 15 minutes. The LD50 value obtained for males was 2580 mg/kg bw and for females 3370 mg/kg bw.

Key study: Acute toxicity – inhalation

Read-across from the supporting substance Methyl acetate (CAS no.: 79-20-9 / EC no.: 201-185 -2). Methyl acetoacetate is a well defined mono-constitutent substance of high purity. Based on the similar structure and properties, the substance Methyl acetate was selected as representative model structure for read-across. Compared to MAA, the selected structure show similar physical-chemical, toxicological and ecotoxicological properties. A data matrix covering all available endpoints was previously published in the EU-Risk assessment Report Vol. 34 of 2003. The available data on MAA and selected model constituent revealed similar properties. For Methyl acetate, Smyth et al (1962) reported a LC0 of 49.2 mg/l/4h and a LC50 of > 49.2 mg/l/4h on rabbits.

Key study: Acute toxicity – dermal

The study was performed according to OECD Guidelines No. 402 and EU-Method B3. A group of ten animals (five males and five females) was given a single, 24 hour, semi‑occluded dermal application of the undiluted test item to intact skin at a dose level of 2000 mg/kg bodyweight.. There were neither deaths nor clinical signs observed. There were no signs of dermal irritation, body weights remained unchanged and necropsy revealed no abnormalities. The LD50 was found to be > 2000 mg/kg body weight.


Justification for selection of acute toxicity – oral endpoint
non-GLP study following OECD-guideline; Klimisch 2

Justification for selection of acute toxicity – dermal endpoint
GLP-study following OECD-guideline; Klimisch 1

Justification for classification or non-classification

Based on the data available the substance is not classified or labeled according to Directive 67/548/EEC (DSD) or Regulation 1272/2008/EC (CLP).